SGLT2 Inhibitors: Glucotoxicity and Tumorigenesis Downstream the Renal Proximal Tubule?

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Background:

• Diabetes mellitus is a leading cause of end-stage renal disease.
• Effective glycemic control is crucial for delaying diabetic complications like kidney disease.
• New anti-diabetic agents are sought to not only control but also restore kidney function.

Purpose of the Study:

• To investigate the renoprotective effects of Sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond proximal tubule cells.
• To explore potential undesired effects of enhanced glucosuria and albuminuria on downstream nephron segments.
• To identify new research avenues for understanding the full renoprotective action of SGLT2 inhibitors.

Main Methods:

• Review of existing studies on SGLT2 inhibitors and their effects on kidney cells and animal models.
• Discussion of potential mechanisms of action and consequences of SGLT2 inhibition.
• Identification of knowledge gaps regarding effects on distal nephron segments.

Main Results:

• SGLT2 inhibitors reduce hyperglycemia by increasing glucosuria via impaired glucose reabsorption in proximal tubules.
• Studies show SGLT2 inhibitors reduce glucotoxicity in isolated proximal tubule cells and markers of kidney damage in diabetic animal models.
• The renoprotective effect on downstream nephron segments remains largely unknown.

Conclusions:

• While SGLT2 inhibitors protect renal proximal tubule epithelial cells (RPTEC), downstream segments may still be exposed to high glucose and albumin levels.
• The impact of sustained glucosuria on distal nephron segments needs further research.
• Further investigation is needed to fully understand the renoprotective mechanisms and potential risks of SGLT2 inhibitors.